Alveogene
Alveogene is targeting the genetic causes of serious respiratory diseases by leveraging the company’s InGenuiTy platform to deliver inhaled gene therapy to the site of action in the lungs.
- What
- Life Sciences
- When
- Sept 2022
- CEO
- David Hipkiss (Executive Chair)
- Status
- Private
- Investment
- Active
- OSE Board Director
- Claire Brown